Ver­sant funds TCR ther­a­py biotech T-knife's $78M+ Se­ries A to boost hu­man­ized T cell mice plat­form

Just a day af­ter an­nounc­ing the for­ma­tion of a start­up in Switzer­land that will de­vel­op al­ter­na­tive TCR cell ther­a­pies, Ver­sant is keep­ing its foot on the gas.

The multi­bil­lion dol­lar life sci­ences VC an­nounced Thurs­day morn­ing it is lead­ing the Se­ries A fund­ing of T-knife, a Ger­man biotech that plans to use its pro­pri­etary hu­man­ized T cell re­cep­tor (HuT­CR) mouse plat­form to treat sol­id tu­mors. T-knife raised about $78.4 mil­lion in the round and hopes to not on­ly de­vel­op its own pipeline but al­so li­cense out its mice for use by oth­er com­pa­nies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER